Roche: Gazyva/Gazyvaro Becomes First FDA-Approved Treatment For Primary Membranous Nephropathy In Adults
Phase III MAJESTY Trial Shows 36.1% Complete Remission At Two Years Versus 5.7% With Tacrolimus
Phase III MAJESTY Trial Shows 36.1% Complete Remission At Two Years Versus 5.7% With Tacrolimus